Merus N.V. announced FDA approval for BIZENGRI (zenocutuzumab-zbco) to treat advanced pancreatic adenocarcinoma and non-small cell lung cancer with NRG1 gene fusion, showing a 40% overall response rate in pancreatic cancer and 33% in NSCLC based on clinical trial data.